Spurred by a new study that showed experimental pain medications with high abuse potential were more likely to make it through drug development and be approved by the FDA than those with low abuse potential, researchers called for expanded research funding to explore pain mechanisms in order to find more nonaddictive drug targets.
Dermot P. Maher, MD, MS, MHS, an assistant professor at the John Hopkins University School of Medicine, in Baltimore, and financial engineering faculty from the